Microperimetric changes after photodynamic therapy for central serous chorioretinopathy

Area of Science:

• Ophthalmology
• Retinal Diseases
• Photodynamic Therapy

Background:

• Central serous chorioretinopathy (CSC) is a condition affecting macular function.
• Standard treatments for CSC may have limitations.
• Verteporfin photodynamic therapy (PDT) is an option for certain retinal conditions.

Purpose of the Study:

• To assess the efficacy of a half-dose verteporfin photodynamic therapy (PDT) regimen.
• To evaluate the impact of half-dose PDT on macular function in central serous chorioretinopathy (CSC).
• To analyze changes in visual acuity and retinal sensitivity post-treatment.

Main Methods:

• An interventional case series involving 24 eyes with CSC.
• Half-dose verteporfin PDT was administered.
• Macular function was assessed using microperimetry (MP-1) and optical coherence tomography (OCT) at baseline and at 1, 3, and 6 months post-treatment, measuring best-corrected visual acuity (BCVA) and retinal sensitivity.

Main Results:

• Significant improvements were observed in BCVA and retinal sensitivity across central and paracentral areas, including the PDT laser spot area.
• Subretinal fluid (SRF) resolved in 83% of eyes within 1 month and in all eyes by 6 months post-treatment.
• No systemic or ocular adverse events related to verteporfin treatment were reported.

Conclusions:

• Half-dose verteporfin PDT is effective in enhancing macular sensitivity in CSC patients over a 6-month period.
• The treatment demonstrates a favorable safety profile.
• Half-dose PDT offers a promising therapeutic option for managing central serous chorioretinopathy.